DrugBiological
Inotuzumab Ozogamicin clinical trials
Also written CMC-544, Besponsa and Way 207294.
Keep track of what changes. Save the Inotuzumab Ozogamicin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
- Besponsa
- 15
Studies by the year they started
48 studies that test it; most in 2019 (5)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 5 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 34
Pfizer (13) · M.D. Anderson Cancer Center (8) · Institute of Hematology & Blood Diseases Hospital, China (5) · Alliance for Clinical Trials in Oncology (2) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Dana-Farber Cancer Institute (1) · Versailles Hospital (1) · University College, London (1)
Often tested with
Tested in the same studies.
Rituximab (9) · Blinatumomab (9) · Vincristine (5) · Prednisone (5) · Venetoclax (4) · Cyclophosphamide (4) · Doxorubicin (2) · Gemcitabine (2)
Studies
Open first, then newest update. How each study uses Inotuzumab Ozogamicin is read from its arms, and is right about nine times in ten.
Testing it · 48
- Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT03150693Written as Inotuzumab Ozogamicin
- Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic LeukemiaNot yet recruitingPhase 2PETHEMA FoundationNCT07862946Written as Inotuzumab Ozogamicin (IO)
- Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALLNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07840976Written as Inotuzumab Ozogamicin (IO)
- A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALLRecruitingPhase 2PfizerNCT05748171Written as Inotuzumab ozogamicin
- Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT05645718Written as Inotuzumab ozogamicin
- Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic LeukemiaRecruitingPhase 1/2Leland MethenyNCT03104491Written as Inotuzumab Ozogamicin
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyRecruitingPhase 3Children's Oncology GroupNCT03959085Written as Inotuzumab Ozogamicin
- Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella TrialNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07643103Written as Inotuzumab Ozogamicin (IO)
- Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)RecruitingPhase 2University of ChicagoNCT04747912Written as Inotuzumab ozogamicin
- Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT02877303Written as Inotuzumab Ozogamicin
- Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline ChemotherapyRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT06985485Written as Blinatumomab and Inotuzumab Ozogamicin
- International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)Not yet recruitingPhase 3Charite University, Berlin, GermanyNCT07476729Written as Inotuzumab ozogamicin (INO)
- Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALLRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06387121Written as Inotuzumab ozogamicin
- Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALLRecruitingPhase 2Sheng-Li Xue, MDNCT05940961Written as Inotuzumab Ozogamicin
- Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALLRecruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT06554626Written as Inotuzumab ozogamicin
- Phase II Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic LeukemiaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06427330Written as Inotuzumab ozogamicin
- Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALLRecruitingPhase 2Nicola GoekbugetNCT03460522Written as Inotuzumab ozogamicin
- Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual DiseaseActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03441061Written as Inotuzumab Ozogamicin
- CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)CompletedPhase 2M.D. Anderson Cancer CenterNCT01134575Written as CMC-544 (Inotuzumab Ozogamycin)
- Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic LeukemiaTerminatedPhase 2M.D. Anderson Cancer CenterNCT03488225Written as Inotuzumab Ozogamicin
See all 48 studies that test Inotuzumab Ozogamicin →
Given in every arm · 9 — Inotuzumab Ozogamicin is usual care beside what is tested
- Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT03739814Written as Inotuzumab Ozogamicin
- A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic LeukemiaNot yet recruitingPhase 1/2BeOne MedicinesNCT07770698Written as Inotuzumab ozogamicin
- Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomabRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT06287229Written as Inotuzumab Ozogamicin
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07493161Written as Inotuzumab ozogamicin
- Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT01371630Written as Inotuzumab Ozogamicin
- A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma PatientsNot yet recruitingPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06087419Written as Inotuzumab Ozogamicin
- Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic LeukemiaActive, not recruitingPhase 2Children's Oncology GroupNCT02981628Written as Inotuzumab Ozogamicin
- Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell TransplantationTerminatedPhase 2M.D. Anderson Cancer CenterNCT03856216Written as Inotuzumab Ozogamicin
- Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALLActive, not recruitingPhase 1University of VirginiaNCT03962465Written as Inotuzumab ozogamicin
Codes
What other systems call Inotuzumab Ozogamicin · ClinicalTrials.gg INT006842
- MeSH (NLM) D000080045Inotuzumab OzogamicinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) P93RUU11P7INOTUZUMAB OZOGAMICINConfirmed FDA, NLM, Wikidata
- RxNorm 1942950Confirmed FDA, Wikidata
- Wikidata Q3799041inotuzumab ozogamicinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71542Inotuzumab OzogamicinOne source FDA
- DrugBank DB05889One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000080045 | Inotuzumab Ozogamicin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | P93RUU11P7 | INOTUZUMAB OZOGAMICIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1942950 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3799041 | inotuzumab ozogamicin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71542 | Inotuzumab Ozogamicin | One source FDA |
| DrugBank | DB05889 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.